Integral DiagnosticsASX:IDX -0.50%75 OCF Yield % is 11.32 as of Jun. 28, 2026, which is 46% above its 10-year median of 7.74. GuruFocus rates ASX:IDX with a GF Score™ of 75/100 and a GF Value™ of A$2.78 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Integral Diagnostics ranks better than 87.91% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Integral Diagnostics's OCF Yield % or its related term are showing as below:
ASX:IDX'
s OCF Yield % Range Over the Past 10 Years
Min: 4.95 Med: 7.74 Max: 17.68
Current: 11.32
During the past 10 years, the highest OCF Yield % of Integral Diagnostics was 17.68%. The lowest was 4.95%. And the median was 7.74%.
ASX:IDX's OCF Yield % is ranked better than 87.91% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.05
vs ASX:IDX: 11.32
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Integral Diagnostics OCF Yield % Related Terms
Integral Diagnostics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integral Diagnostics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ASX:IDX) has a OCF Yield % of 11.32 as of Jun. 28, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Integral Diagnostics and its competitors. This is 46% above median its historical median of 7.74. Over the past decade, Integral Diagnostics' OCF Yield % has ranged from 4.95 to 17.68. According to the industry distribution chart, Integral Diagnostics ranks #26 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 12.1%.
Is Integral Diagnostics' OCF Yield % too high?
Integral Diagnostics' current OCF Yield % of 11.32 is 46% above median its 10-year median of 7.74. Over the past 10 years, this metric has ranged from a low of 4.95 to a high of 17.68. The Medical Diagnostics & Research industry median OCF Yield % is 1.05. Integral Diagnostics' value of 11.32 is 978.1% above this industry median. Based on the distribution chart, Integral Diagnostics ranks #26 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Integral Diagnostics has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' OCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #26 out of 215 companies for OCF Yield %. This places Integral Diagnostics in the top 12% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 1.05. Integral Diagnostics' value of 11.32 is 978.1% above this benchmark. Historically, Integral Diagnostics' own OCF Yield % has ranged from 4.95 to 17.68 over the past decade. While the company's 10-year median is 7.74 vs. the industry median of 1.05, Integral Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.05, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current OCF Yield % of 11.32 is 978.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current OCF Yield % is 11.32, which is 46% above median its own 10-year median of 7.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.78, compared to a current price of A$2.00 — trading 28.1% below its estimated fair value. The current OCF Yield % is 11.32, which is 46% above median its 10-year median of 7.74 and 978.1% above the Medical Diagnostics & Research industry median of 1.05. Integral Diagnostics' overall GF Score™ is 75/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current OCF Yield % is 11.32 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.00 is trading 28.1% below its estimated GF Value™ of A$2.78.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
OCF Yield %: 11.32 (46% above median its 10-year median of 7.74)
GF Value™: A$2.78 vs. price of A$2.00 (28.1% below fair value)
Industry Position: 978.1% above the Medical Diagnostics & Research median (#26 of 215)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
75GF Score
Get the complete analysis for ASX:IDX
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
